Cefadroxil sodium | CAS# 42284-83-3 (salt) | broad-spectrum antibiotic

MedKoo Cat#: 412494 | Name: Cefadroxil sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefadroxil sodium is the salt from of Cefadroxil, a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections. It is a bactericidal antibiotic. Cefadroxil is a semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Chemical Structure

Cefadroxil sodium

CAS#42284-83-3 (sodium)

Theoretical Analysis

MedKoo Cat#: 412494

Name: Cefadroxil sodium

CAS#: 42284-83-3 (sodium)

Chemical Formula: C16H16N3NaO5S

Exact Mass: 0.0000

Molecular Weight: 385.37

Elemental Analysis: C, 49.87; H, 4.19; N, 10.90; Na, 5.97; O, 20.76; S, 8.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

50370-12-2 (free acid) 66592-87-8 (hydrate) 42284-83-3 (sodium)

Synonym

Cefadroxil sodium; UNII-SSZ6380I0I

IUPAC/Chemical Name

sodium;(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

InChi Key

GQOVFIUWRATNJC-CYJZLJNKSA-M

InChi Code

InChI=1S/C16H17N3O5S.Na/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8;/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24);/q;+1/p-1/t10-,11-,15-;/m1./s1

SMILES Code

O=C(C(N12)=C(C)CS[C@]2([H])[C@H](NC([C@H](N)C3=CC=C(O)C=C3)=O)C1=O)[O-].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 385.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kim EJ, Kim JE, Ro YS, Ko JY. Cefaclor-Induced Generalized Fixed Drug Eruption. Ann Dermatol. 2015 Aug;27(4):465-6. doi: 10.5021/ad.2015.27.4.465. Epub 2015 Jul 29. PubMed PMID: 26273172; PubMed Central PMCID: PMC4530166. 2: Qian JQ, Correra TC, Li J, Maître P, Song DQ, Hu CQ. Differentiation of cefaclor and its delta-3 isomer by electrospray mass spectrometry, infrared multiple photon dissociation spectroscopy and theoretical calculations. J Mass Spectrom. 2015 Jan;50(1):265-9. doi: 10.1002/jms.3510. PubMed PMID: 25601701. 3: Thomas PW, Cammarata M, Brodbelt JS, Fast W. Covalent inhibition of New Delhi metallo-β-lactamase-1 (NDM-1) by cefaclor. Chembiochem. 2014 Nov 24;15(17):2541-8. doi: 10.1002/cbic.201402268. Epub 2014 Oct 10. PubMed PMID: 25302694. 4: Yoo HS, Kim SH, Kwon HS, Kim TB, Nam YH, Ye YM, Park HS. Immunologic evaluation of immediate hypersensitivity to cefaclor. Yonsei Med J. 2014 Nov;55(6):1473-83. doi: 10.3349/ymj.2014.55.6.1473. PubMed PMID: 25323882; PubMed Central PMCID: PMC4205685. 5: Huang C, Wang W, Miao L. Determination of cefaclor by UPLC-MS-MS for a Chinese pharmacokinetic study. J Chromatogr Sci. 2014 Aug;52(7):636-40. doi: 10.1093/chromsci/bmt092. Epub 2013 Jul 9. PubMed PMID: 23839802. 6: Vetter F, Pohl J, Pohl B, Bracher F. Analysis of cefaclor in novel chocolate-based camouflage capsules. Pharmazie. 2014 Jun;69(6):455-7. PubMed PMID: 24974581. 7: van de Streek J, Rantanen J, Bond AD. Structures of cefradine dihydrate and cefaclor dihydrate from DFT-D calculations. Acta Crystallogr C. 2013 Nov;69(Pt 11):1229-33. doi: 10.1107/S0108270113026863. Epub 2013 Oct 19. PubMed PMID: 24192164. 8: Lutfullah, Khan F, Rahman N. Solid phase extraction and determination of Cr(III) by spectrophotometry using cefaclor as a complexing reagent and FAAS. Environ Monit Assess. 2013 Jun;185(6):4959-67. doi: 10.1007/s10661-012-2917-1. Epub 2012 Oct 7. PubMed PMID: 23054281. 9: Zhang Z, Xiang Y, Wang B, Chen H, Cai X, Wang X, Mei L, Zheng Y. Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions. Eur J Pediatr. 2013 Apr;172(4):537-43. doi: 10.1007/s00431-012-1926-y. Epub 2013 Jan 8. PubMed PMID: 23296953. 10: Rasool BK, Fahmy SA. Development of coated beads for oral controlled delivery of cefaclor: In vitro evaluation. Acta Pharm. 2013 Mar;63(1):31-44. doi: 10.2478/acph-2013-0003. PubMed PMID: 23482311. 11: Bottaro G, Biasci P, Lo Giudice M, Mele G, Montanari G, Napoleone E, Santucci A, Tucci PL, Fano M, Biraghi MG. [5 days Cefaclor vs. 10 days amoxicillin/clavulanate in the treatment of childhood streptococcal pharyngitis. Data from a randomized clinical trial]. Minerva Pediatr. 2012 Jun;64(3):341-6. Italian. PubMed PMID: 22555328. 12: Chen J, Jiang B, Lou H, Yu L, Ruan Z. Bioequivalence studies of 2 oral cefaclor capsule formulations in chinese healthy subjects. Arzneimittelforschung. 2012 Mar;62(3):134-7. doi: 10.1055/s-0031-1298012. Epub 2012 Jan 27. PubMed PMID: 22286978. 13: Tarawneh KA, Halasah ZA, Khleifat AM, Batarseh MI, Khleifat KM, Al-Mustafa AH. Evaluation of cefaclor oral suspensions stability using reversed phase high performance liquid chromatography and antimicrobial diffusion methods. Pak J Pharm Sci. 2011 Jul;24(3):303-13. PubMed PMID: 21715263. 14: Tristram SG, Littlejohn R, Bradbury RS. blaROB-1 presence on pB1000 in Haemophilus influenzae is widespread, and variable cefaclor resistance is associated with altered penicillin-binding proteins. Antimicrob Agents Chemother. 2010 Nov;54(11):4945-7. doi: 10.1128/AAC.00263-10. Epub 2010 Aug 16. PubMed PMID: 20713676; PubMed Central PMCID: PMC2976118. 15: Endo R, Yamane N, Tamayose MH, Uchibori KK, Nakasone I. [A simple disk diffusion test to identify beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae--application of cephalexin, cefsulodin and cefaclor disks]. Rinsho Byori. 2010 Oct;58(10):963-71. Japanese. PubMed PMID: 21077285. 16: Li JM, Li C, Jiang Y, Ren SM. Pretreatment of plasma samples by a novel hollow fiber centrifugal ultrafiltrate device for the determination of cefaclor concentrations in human plasma. J Chromatogr A. 2010 Oct 29;1217(44):6824-8. doi: 10.1016/j.chroma.2010.08.059. Epub 2010 Sep 20. PubMed PMID: 20863507. 17: Cefaclor: serum sickness. Prescrire Int. 2010 Apr;19(106):75. PubMed PMID: 20568494. 18: Ma J, Bellon M, Wishart JM, Young RL, Jones KL, Horowitz M, Rayner CK. Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans. Regul Pept. 2010 Jan 8;159(1-3):156-9. doi: 10.1016/j.regpep.2009.11.009. Epub . PubMed PMID: 19914303. 19: Medenecka B, Jelińska A, Zajac M, Bałdyka M, Juszkiewicz K, Oszczapowicz I. Stability of the crystalline form of cefaclor monohydrate and its pharmaceutical preparations. Acta Pol Pharm. 2009 Sep-Oct;66(5):563-9. PubMed PMID: 19894653. 20: Novembre E, Mori F, Pucci N, Bernardini R, Romano A. Cefaclor anaphylaxis in children. Allergy. 2009 Aug;64(8):1233-5. doi: 10.1111/j.1398-9995.2009.02043.x. Epub 2009 Apr 6. PubMed PMID: 19385950.